Pulmonary arterial hypertension, PAH is a lung disease that affects 10,000 Canadians. Symptoms include persistent shortness of breath, chest pain, fatigue and dizzy spells. A new daily oral treatment option is now available in Canada. Distributed...
Read the full transcript »

Female Speaker: Pulmonary Arterial Hypertension or PAH is a serious condition for which there are approved treatments but no cure. This disease affects people of all genders, races and ages, but it's more prevalent among women in their childbearing years. Adcirca is the first once a day PDE5 inhibitor oral therapy for the treatment of PAH. It offers significant improvement in exercise capacity and has shown to consistently improve certain aspects of health related quality of life for patients with PAH, such as climbing stairs, during laundry or even dressing. Dr. Sanjay Mehta is a Canadian physician who specializes in PAH. Dr. Sanjay Mehta: Pulmonary Arterial Hypertension is a very important and serious disease of the lungs, where the blood vessels become narrowed and sometimes scarred to the point of being closed. As a result patients experience shortness of breath, tiredness, and eventually weakness of the right side of the heart with passing out, swelling and eventually high risk of death. Adcirca is a very important new, exciting treatment for Pulmonary Arterial Hypertension, it's important for several reasons. First it involves a very important pathway that we know plays a role in Pulmonary Arterial Hypertension, the PDE5 or phosphodiesterase pathway. As well this new once a day oral therapy has been shown to be effective in studies. Patients have had better exercise capacity and better quality of life, so simple things like being able to walk upstairs more comfortably and play with your grandkids more easily. Female Speaker: Due to the severe pressure this disease has on lung capacity, patients with PAH are forced to reduce their exercise capacity in order to breath. A recent clinical trial called PHIRST followed 405 patients with PAH to track progression. Dr. Sanjay Mehta: The Phase-3 trial of Adcirca showed that patients taking 40 milligrams once daily had a very important improvement in six minute walk distance with 33 meters compared to the placebo group. As well we know that patients with Pulmonary Arterial Hypertension get worse, they either get hospitalized and need to be transplanted and very importantly Adcirca had an effect of reducing the risk of getting worse in PAH. Female Speaker: The introduction of Adcirca offers the healthcare community a new treatment option for managing this serious lung disorder. To learn more about Adcirca patients and caregivers should speak to their healthcare provider and visit phacanada.ca.

Advertisement
Advertisement
Advertisement